Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003 [Microdose]
October 15, 2024
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies [Benzinga]
October 8, 2024
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit [Microdose]
September 25, 2024
Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit [Benzinga]
September 25, 2024
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research [Benzinga]
September 25, 2024
This Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health [Smart Money Podcast]
September 16, 2024
The Future Of MDMA-Assisted Therapy After FDA Rejection — Where Do We Go Now? [Clinical Leader]
August 16, 2024
FDA Rejects MDMA-Assisted PTSD Therapy [Psychiatrist.com]
August 14, 2024
FDA Rejected MDMA-Assisted PTSD Therapy: Psychedelic Industry Responds [Microdose]
August 14, 2024
Enveric Biosciences Announces Promising Preclinical Results for EB-003 [Microdose]
July 25, 2024
‹
1
2
3
4
…
13
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
